Oral antifungal drug, NAILIN, receives approval for treatment of onychomycosis in Japan
by Press Release from Outbreak News Today on (#3DX4P)
Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018. Sato Pharma and Eisai Co., Ltd. are jointly providing information on its proper use. Fosravuconazole, the active ingredient of ["]
The post Oral antifungal drug, NAILIN, receives approval for treatment of onychomycosis in Japan appeared first on Outbreak News Today.